Quantel Medical’s selective laser trabeculoplasty (SLT) glaucoma laser has been approved by the FDA.
Clermont-Ferrand, France-Quantel Medical’s selective laser trabeculoplasty (SLT) glaucoma laser has been approved by the FDA.
The laser, called Solutis, offers several features, which enable it to be integrated into a hospital or clinical setting.
The laser was designed to be adaptable to a physician’s current slit lamp, which then eliminates the need for dedicated space and lowers end-user cost.
The FDA’s clearance of the laser follows the expiration of a patent issued to Massachusetts General Hospital, which restricted Quantel and several other laser manufactures from marking SLT within the United States.
Quantel has been providing SLT technology outside the United States since 2007.
“This FDA market clearance of our SLT laser marks an important step in Quantel’s strategy for the U.S. market,” said Jean-Marc Gendre, chief executive officer of Quantel. “(The laser) has proven to be an attractive laser solution worldwide.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.